RxDoctor Payments Data

Tonya Sheppard

Adult Health · New Bern, NCNPI 1972384899

Payments from drug & device makers

$1,865in general payments, 2019–2025

Across 95 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$331
  • E.r. Squibb & Sons, L.L.C.$177
  • Amgen$158
  • Sanofi-aventis U.S. LLC$157
  • Scpharmaceuticals Inc.$139
  • Merck$136
  • plus $767 from 15 others

What the payments were for

  • Food & beverage$1,865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,865 in reported general payments places this provider in the 75th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$85,340
Medicare patients
568
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$104,053
JardianceEmpagliflozin70$50,586
EntrestoSacubitril/Valsartan44$36,153
XareltoRivaroxaban26$22,587
BrilintaTicagrelor12$11,369
FarxigaDapagliflozin Propanediol12$7,320
Ranolazine ErRanolazine18$2,207
Metoprolol Succinate182$2,009
Rosuvastatin Calcium76$1,071
Atorvastatin Calcium105$896
Nitroglycerin22$834
Furosemide143$815
Potassium Chloride27$598
Carvedilol70$584
Isosorbide Mononitrate ErIsosorbide Mononitrate72$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$52$50,58670 claims
NovartisEntresto$331$36,15344 claims
Johnson & JohnsonXarelto$127$22,58726 claims
AstraZenecaBrilinta, Farxiga$16$18,68924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 adult health providers in North Carolina.

Other adult health in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →